Cargando…

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys

Inhibition of cholesteryl ester transfer protein (CETP) increases HDL cholesterol (HDL-C) levels. However, the circulating CETP level varies and the impact of its inhibition in species with high CETP levels on HDL structure and function remains poorly characterized. This study investigated the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brodeur, Mathieu R., Rhainds, David, Charpentier, Daniel, Mihalache-Avram, Teodora, Mecteau, Mélanie, Brand, Geneviève, Chaput, Evelyne, Perez, Anne, Niesor, Eric J., Rhéaume, Eric, Maugeais, Cyrille, Tardif, Jean-Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496027/ https://www.ncbi.nlm.nih.gov/pubmed/28515138 http://dx.doi.org/10.1194/jlr.M068940

Ejemplares similares

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
por: Brodeur, Mathieu R., et al.
Publicado: (2022)

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
por: Niesor, Eric J, et al.
Publicado: (2021)

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes
por: Tardif, Jean-Claude, et al.
Publicado: (2016)

Optimisation of Reference Genes for Gene-Expression Analysis in a Rabbit Model of Left Ventricular Diastolic Dysfunction
por: Nachar, Walid, et al.
Publicado: (2014)

Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits
por: Nachar, Walid, et al.
Publicado: (2019)

Colchicine reduces lung injury in experimental acute respiratory distress syndrome
por: Dupuis, Jocelyn, et al.
Publicado: (2020)

Colchicine reduces atherosclerotic plaque vulnerability in rabbits
por: Roubille, François, et al.
Publicado: (2021)

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
por: Niesor, Eric J., et al.
Publicado: (2010)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Validating Intravascular Imaging with Serial Optical Coherence Tomography and Confocal Fluorescence Microscopy
por: Tardif, Pier-Luc, et al.
Publicado: (2016)

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
por: Niesor, Eric J.
Publicado: (2015)

HDL as Bidirectional Lipid Vectors: Time for New Paradigms
por: Luna-Luna, María, et al.
Publicado: (2022)

Anacetrapib as a potential cardioprotective strategy
por: Di Bartolo, Belinda A, et al.
Publicado: (2017)

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
por: Kühnast, Susan, et al.
Publicado: (2015)

Impact of ADCY9 Genotype on Response to Anacetrapib
por: Hopewell, Jemma C., et al.
Publicado: (2019)

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
por: Schwartz, Gregory G., et al.
Publicado: (2020)

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
por: Goldberg, Alyse S, et al.
Publicado: (2012)

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
por: Sammons, E, et al.
Publicado: (2021)

In Vivo Near-Infrared Fluorescence Imaging of Atherosclerosis Using Local Delivery of Novel Targeted Molecular Probes
por: Bertrand, Marie-Jeanne, et al.
Publicado: (2019)

Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34(+) Cells in Patients after an Acute Coronary Syndrome
por: Gebhard, Catherine, et al.
Publicado: (2017)

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
por: Stein, Evan A., et al.
Publicado: (2010)

Erratum to: Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Publicado: (2022)

How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations
por: Äijänen, Tarja, et al.
Publicado: (2014)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
por: Miyares, Marta A, et al.
Publicado: (2012)

Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
Publicado: (2012)

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
por: Millar, John S., et al.
Publicado: (2017)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
por: Johns, Douglas G., et al.
Publicado: (2019)

MARMOSET MONKEYS AS A MODEL OF AGING
por: Tardif, Suzette, et al.
Publicado: (2019)

Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein Cholesterol
por: Low‐Kam, Cécile, et al.
Publicado: (2018)

The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits
por: Wu, Ben J., et al.
Publicado: (2019)

An in silico model of retinal cholesterol dynamics (RCD model): insights into the pathophysiology of dry AMD
por: Zekavat, Seyedeh Maryam, et al.
Publicado: (2017)

The Current Status of Research on High-Density Lipoproteins (HDL): A Paradigm Shift from HDL Quantity to HDL Quality and HDL Functionality
por: Cho, Kyung-Hyun
Publicado: (2022)

Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
por: Vyletelová, Veronika, et al.
Publicado: (2022)

HDL Cholesterol Story Is Dead: Long Live HDL!
por: Simha, Vinaya, et al.
Publicado: (2016)

Effect of HDL composition and particle size on the resistance of HDL to the oxidation
por: Shuhei, Nakanishi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kptjjf524fptcj2sfjiksh5na6